$9,427.7 Million Neuromodulation Devices Markets – Global Forecast To 2029 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Neuromodulation Devices Global Market- Forecast To 2029” report has been added to ResearchAndMarkets.com’s offering.

The neuromodulation devices global market is expected to reach $9,427.7 million by 2029 growing at a high single digit CAGR from 2022 to 2029.

The factors such as increasing prevalence of chronic pain conditions, central nervous system disorders such as Parkinson disease, Alzheimer disease, Multiple sclerosis, Epilepsy and others (According to U.S. Parkinson’s U.S. foundation, nearly one million people in the U.S. are living with Parkinson’s disease (PD) and this number is expected to rise to 1.2 million by 2030.

The prevalence of Parkinson’s in the U.K. is a total of about 127,000 people living with the disease, The prevalence of epilepsy is estimated to be 5.0 million people in U.S. in 2022), low approval rate of CNS drugs and favorable reimbursement scenario in major markets are driving the neuromodulation market.

The emergence of neuromodulation as add-on therapy, technological innovations in neuromodulation, expansion in emerging markets and the rise in the number of clinical studies performed provides immense opportunities to the neuromodulation market. However, side effects and risks associated with the use, lack of trained professionals, availability of alternative treatments and stringent regulatory guidelines are expected to hamper the market growth.

Based on the product, the neuromodulation global market is segmented into invasive neuromodulation devices and non-invasive neuromodulation devices. Among these, invasive neuromodulation devices segment accounted for the largest revenue in 2022 and is expected grow at a high single digit CAGR from 2022 to 2029.

Invasive neuromodulation segment is further segmented into Spinal Cord Stimulator (SCS), Deep Brain Stimulator (DBS), Sacral Nerve Stimulator (SNS), Vagus Nerve Stimulator (VNS), Hypoglossal Nerve Stimulator (HGNS) and others. Among invasive neuromodulation devices, Spinal cord stimulator (SCS) segment accounted for the largest revenue in 2022 and is expected to grow at a mid single digit CAGR from 2022 to 2029.

Based on the application, the neuromodulation devices global market is segmented into Pain Management, Central Nervous System, Gastroenterology and Urology, Obstructive Sleep Apnea (OSA) and other. Among applications, pain management segment accounted for the largest revenue in 2022 and is grow at a mid single digit CAGR from 2022 to 2029.

Pain management is further segmented into chronic pain, failed back surgery syndrome (FBSS) and others. Among pain management, chronic pain segment is the largest and fastest growing segment. Central Nervous System is further segmented into Parkinson’s disease, Dystonia, Epilepsy and others include Obsessive Compulsive Disorder (OCD), Depression, Stroke, and Mood disorders, Anxiety, Central Sleep Apnea and Multiple Sclerosis.

Among Central Nervous System disorders, Parkinson’s disease segment accounted for the largest revenue in 2022 and is expected grow at a CAGR mid single digit from 2022 to 2029. Epilepsy segment is the fastest growing segment in 2022 and is expected grow at a double digit CAGR from 2022 to 2029. Gastroenterology and Urology is further segmented into Gastroparesis, Urinary Incontinence and Faecal Incontinence. Among Gastroenterology and Urology, Urinary Incontinence segment accounted for the largest and fastest growing segment.

Based on the end-user, the neuromodulation devices global market is segmented into Hospitals and Ambulatory Surgery Centers, Clinics and Physiotherapy Centers and Others include Home care, Academics and Research Institutes. Among end-user, Hospitals and Ambulatory Surgery Centers is the largest and fastest growing segment and is expected grow at high single digit CAGR from 2022 to 2029.

The factors such as increasing healthcare expenditure, increasing incidence of chronic pain problems, persistently increasing geriatric population with age related CNS disorders parkinson’s, alzheimer’s, epilepsy and incontinence problems, adoption of neurostimulation devices for the treatment of movement disorders, epilepsy, pain, and depression with rising number of approvals, increasing number of neuromodulation procedures and hospitals, presence of major players, launch of advanced neuromodulation devices by the companies, introduction of remote Neuromodulation Patient-Care Technology to increase the adoption, rising funding for start-up companies for developing unique neuromodulation technologies and presence of dedicated non-profit organization devoted to the advancement of the field of neuromodulation are driving the neuromodulation market in the region.

Asia-Pacific is the fastest growing segment and is expected grow at a double digit CAGR from 2022 to 2029

The factors such as increasing healthcare expenditure, increasing aging population, increasing incidence and prevalence of targeted disease such as Chronic Pain, Parkinson’s disease, Alzheimer’s disease and incontinence problems, increasing adoption of implantable devices, high acceptance of technological advancements, government initiatives to increase awareness by education campaigns and development of neuromodulation devices and their approval in other markets boosts the growth of neuromodulation market in region.

The neuromodulation devices global market is a highly consolidated market hence all the existing players in this market are involved in developing new and advanced technologies to maintain their market shares.

Some of the key players in neuromodulation devices global market include

Abbott Laboratories

Axonics Inc.

Bioventus (Bioness Inc)

Boston Scientific Corporation

Inspire Medical System, Inc.

Laborie Medical Technologies, Inc.

Livanova plc

Medtronic plc

Neuropace, Inc.

Nevro Corpoartion

Market Analysis

Drivers and Opportunities

Growing Prevalence of Treatment Resistant Chronic Pain Conditions

Growing Prevalence of Central Nervous System Disorders Such as Parkinson Disease, Alzheimer Disease, Multiple Sclerosis, Epilepsy and Others

Low Approval Rate of Cns Drugs

Favorable Reimbursement Scenario in Major Markets

The Emergence of Neuromodulation as Add-On Therapy

Technological Innovations in Neuromodulation

Expansion in Emerging Markets

The Rise in the Number of Clinical Studies Performed

Restraints and Threats

Side Effects and Risks Associated with the Use

Lack of Trained Professionals

Availability of Alternative Treatments

Stringent Regulatory Guidelines

Regulatory Affairs

Clinical Trials Data

Technological Advancements

Rechargeable Systems

Focused Ultrasound (Fus)

Miniaturization

Portable Nueromodulation Systems (Pons)

Wearable Neuromodulation Technology

Trans-Spinal Direct Current Stimulation (Tsdcs)

Nano-Neuromodulation

Bioactive Coatings

Transcutaneous Vagus Nerve Stimulation

Porter’s Five Force Analysis

Supply Chain Analysis

Reimbursement Scenario

Funding Scenario

Market Share Analysis by Major Players

Neuromodulation Devices Number of Units Based on Region

Market Penetration

Neuromodulation Devices Company Comparison Table Based on Revenue, Technology, Products and Application

For more information about this report visit https://www.researchandmarkets.com/r/k20dei

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.